Author: Lee, Mi Suk; Oh, Jee Youn; Kang, Cheol-In; Kim, Eu Suk; Park, Sunghoon; Rhee, Chin Kook; Jung, Ji Ye; Jo, Kyung-Wook; Heo, Eun Young; Park, Dong-Ah; Suh, Gee Young; Kiem, Sungmin
Title: Guideline for Antibiotic Use in Adults with Community-acquired Pneumonia Document date: 2018_6_26
ID: sl4u8e6e_251
Snippet: According to previous literatures, the 23-valent polysaccharide pneumococcal vaccine prevented invasive pneumococcal diseases in 44-47% of older adults aged 65 years or older [213, 214] , and its effectiveness was slightly reduced in patients with chronic diseases [215] . Numerous cohort studies have recently demonstrated that the vaccine can reduce the incidence of pneumonia, pneumococcal pneumonia, hospitalization due to pneumonia, and deaths b.....
Document: According to previous literatures, the 23-valent polysaccharide pneumococcal vaccine prevented invasive pneumococcal diseases in 44-47% of older adults aged 65 years or older [213, 214] , and its effectiveness was slightly reduced in patients with chronic diseases [215] . Numerous cohort studies have recently demonstrated that the vaccine can reduce the incidence of pneumonia, pneumococcal pneumonia, hospitalization due to pneumonia, and deaths by pneumonia [216] [217] [218] [219] [220] [221] . However, some have reported that the vaccine has no preventive effects against pneumonia, or hospitalization due to pneumonia [222, 223] . Patients who have asplenia, who are of advanced age, or who are in a high-risk group must be revaccinated after five years. The safety and immunogenicity of the vaccine have been verified in numerous studies [224] [225] [226] .
Search related documents:
Co phrase search for related documents- advanced age and cohort study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68
- advanced age and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- advanced age and high risk group: 1, 2, 3
- advanced age and old adult: 1
- advanced age and pneumococcal pneumonia: 1
- advanced age and pneumococcal vaccine: 1, 2
- advanced age and pneumonia death: 1, 2, 3, 4, 5, 6, 7, 8
- advanced age and pneumonia hospitalization: 1, 2, 3, 4, 5, 6
- advanced age and polysaccharide pneumococcal vaccine: 1, 2
- advanced age and previous literature: 1
- chronic disease and cohort study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- chronic disease and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- chronic disease and high risk group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- chronic disease and immunogenicity safety: 1, 2
- chronic disease and invasive pneumococcal disease: 1
- chronic disease and numerous study: 1
- chronic disease and old adult: 1, 2, 3, 4
- chronic disease and pneumococcal disease: 1, 2, 3
- chronic disease and pneumococcal pneumonia: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date